Newsletters
Europe’s medicines regulator has moved to clear a new dual-purpose vaccine, as the human medicines committee of the European Medicines Agency recommended approval of a combined COVID-19 and seasonal influenza shot developed by Moderna for adults aged 50 years and older.
The vaccine, known as mCombriax, is an mRNA-based formulation designed to protect against both SARS-CoV-2 and circulating influenza strains in a single injection.
According to European health authorities, clinical studies demonstrated that immune responses generated by the combined vaccine were comparable to those observed when separate COVID-19 and influenza vaccines were administered.
Regulators reported that the safety profile of the vaccine was consistent with existing immunizations, with commonly observed side effects including injection site pain, fatigue, and muscle discomfort, generally classified as mild to moderate.
The recommendation will now be reviewed by the European Commission, which is responsible for issuing a final authorization decision. Such approvals are typically adopted following a positive scientific opinion from the EMA.
If authorized, the vaccine would become available across member states of the European Union as well as countries within the European Economic Area.
Set as preferred source
Set as preferred source
1 min read
1 min read
